Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.

Front Oncol · 2022 · PMC9589420 · PMID 36300092

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the sorafenib arm, high s-c-KIT and low HGF showed a trend towards enhanced survival ( P -values of interaction 0.081 and 0.073, respectively) ( 137 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.